Xencor
Xencor develops engineered antibodies and cytokines for cancer and autoimmune disease treatment, with a broad pipeline of drug candidates and multiple clinical programs.
Company Overview
Xencor is a biotechnology firm focused on developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. The company boasts a wide-ranging pipeline of drug candidates tailored for these conditions, with over 20 programs currently undergoing clinical testing and numerous others in preclinical stages. Their innovations are centered around XmAb Fc domains, which enhance immune modulation and cancer targeting.
Technological Innovations
Xencor's XmAb technology encompasses Fc domains which can be incorporated into nearly any antibody. This innovation is pivotal in creating highly selective immune modulators and targeted cancer therapies. The technology addresses multiple disease targets while improving half-life, stability, and manufacturing ease. Four primary XmAb Fc domains enhance therapeutic antibody performance in a range of applications, such as immune regulation, cytotoxic potency, and creating bispecific antibody structures.
Pipeline and Programs
Xencor is advancing more than 20 clinical programs involving XmAb antibodies and cytokines. Key candidates include XmAb306, XmAb808, XmAb662, XmAb541, XmAb564, and XmAb819. These candidates target various cancers and autoimmune diseases. Notable products include Vudalimab and Plamotamab, each designed to target multiple disease markers for more effective treatments.
Strategic Partnerships
Xencor has formed strategic partnerships with prominent pharmaceutical companies such as Novartis, Amgen, Alexion, Incyte, Genentech, and Aimmune Therapeutics. These collaborations leverage Xencor's XmAb Fc domain technology to develop and market innovative therapies. Currently, three XmAb medicines are marketed by partners, demonstrating the commercial viability and therapeutic potential of Xencor's technologies.
Corporate Information
Xencor is a publicly traded company listed on the NASDAQ stock exchange under the symbol XNCR. The company's headquarters are located in Pasadena, CA, with an additional office in San Diego, CA. Their mission is to develop superior therapies for patients by enhancing the performance and versatility of antibody and cytokine treatments.